期刊文献+

乳腺癌组织中HER-2、PCNA、Bcl-2、Bax表达的临床意义 被引量:7

Clinical Significance of HER-2,PCNA,Bcl-2 and Bax Expression in Breast Cancer Tissue
原文传递
导出
摘要 目的:研究原癌基因人表皮生长因子受体2(HER-2)、细胞增殖标志物增殖细胞核抗原(PCNA)和凋亡相关基因Bcl-2、Bax在乳腺癌组织中的表达及其与淋巴结转移、临床分期等因素的关系。方法:应用免疫组化Envision二步法检测50例乳腺癌根治术后标本中HER-2、PCNA、Bcl-2、Bax蛋白的表达。结果:乳腺癌组织中HER-2、PCNA、Bcl-2、Bax的表达率分别为44%、82%、48%、54%。HER-2表达率在淋巴结转移组增高(P<0.05);PCNA表达率在肿瘤直径大组明显增高(P<0.01);Bcl-2表达率与年龄、肿瘤大小、淋巴结转移及临床分期无关;Bax表达率在淋巴结转移组及临床分期晚组增高(P<0.05)。相关分析显示,HER-2、Bax表达与淋巴结转移呈正相关(P<0.05)。结论:联合检测HER-2、PCNA、Bcl-2、Bax可作为判断乳腺癌预后的可靠指标。 OBJECTIVE:To study the expressions of HER-2,PCNA,Bcl-2 and Bax in breast cancer tissue and their relationships with lymph node metastasis,clinical stage and other prognostic factors.METHODS:The expressions of HER-2,PCNA,Bcl-2,and Bax in 50 specimens of breast cancer were detected by immunohistochemistry with Envision staining.RESULTS:The expression rates of HER-2,PCNA,Bcl-2 and Bax in breast cancer tissues were 44%,82%,48% and 54%,respectively.HER-2 positive expression rate was significantly high in lymph node metastasis cases (P0.05).PCNA expression was related with tumor size (P0.01).Bcl-2 expression had no significant relation with the age,tumor size,lymph node metastasis or clinical stage.Bax positive expression rate was significantly high in lymph node metastasis and late stage cases (P0.05).Correlative analysis indicated the expressions of HER-2 and Bax were up regulated with lymph node metastasis (P0.05).CONCLUSION:HER-2,PCNA,Bcl-2,and Bax can be markers for estimating the prognosis of breast cancer.
出处 《中国药房》 CAS CSCD 北大核心 2011年第30期2853-2855,共3页 China Pharmacy
关键词 乳腺肿瘤 免疫组化 HER-2 PCNA BCL-2 BAX Breast neoplasm Immunohistochemistry HER-2 PCNA Bcl-2 Bax
  • 相关文献

参考文献13

  • 1WolffAC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol, 2007,25(1) : 118. 被引量:1
  • 2Hussein MR, Abd-Elwahed SR, Abdulwahed AR. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcino-as of the breast[J]. Cell Biol lnt, 2008,32 (6) : 698. 被引量:1
  • 3付强,于世英,许三鹏.乳腺癌HER2过度表达预后相关因素研究[J].肿瘤防治研究,2008,35(S1):9-11. 被引量:8
  • 4Nichols DW, Wolff D J, Self S, et al. A testing algorithm for determination of HER2 status in patients with breast cancer [J]. Ann Clin Lab Sci, 2002,32 ( 1 ) : 3. 被引量:1
  • 5Kostopoulos I, Arapantoni-Dadioti P, Gogas H, et al. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Breast Cancer Res Treat, 2006,96 (3) : 251. 被引量:1
  • 6李明,闫丰,邰智慧,李瑞伟,张涛,朱红成.CerbB-2、P53及PCNA在乳腺癌组织中的表达及其临床意义[J].山东医药,2010,50(24):55-56. 被引量:8
  • 7Ando T, Kawabe T, Ohara H, et al. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage[J]. JBiol Chem, 2001,276(46) : 42 971. 被引量:1
  • 8李艳萍,张斌,喻卫红,吕大鹏,郭怡辉,高宏.Bcl-2、C-erbB2和PCNA表达与乳腺癌新辅助治疗疗效关系的研究[J].中国肿瘤临床与康复,2007,14(1):8-10. 被引量:6
  • 9张德才,张景华,汪萍,何津,刘远廷,李景武.C-erbB2、PCNA、ER、PR在126例乳腺癌中的表达及临床意义[J].现代肿瘤医学,2009,17(10):1874-1877. 被引量:18
  • 10Lee KH, Im SA , Oh DY, et al. Prognostic significance of Bcl-2 expression in stage IU breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy[J]. BMC Cancer, 2007,7 : 63. 被引量:1

二级参考文献47

共引文献54

同被引文献57

  • 1刘恒戈.内分泌药物治疗乳腺癌的临床应用进展[J].中国药房,2005,16(10):791-793. 被引量:6
  • 2杜俊蓉,白波,余彦,汪程远,钱忠明.当归挥发油研究新进展[J].中国中药杂志,2005,30(18):1400-1406. 被引量:110
  • 3朱壮彦,糜若然,刘静.CYP1B1基因多态性与卵巢癌易感性的研究[J].现代妇产科进展,2006,15(3):184-187. 被引量:14
  • 4刘鹏,刘艳,孙慧.小鼠乳腺癌中p53与bcl-2/bax基因表达的相关性研究[J].中华实验外科杂志,2007,24(2):176-178. 被引量:11
  • 5Tsujimoto Y,Yunis J,Onorato-Showe L, et al. Molecu- lar cloning of the chromosomal breakpoint of B-cell lym- phomas and leukemias with the t (11+14) chromosome translocation [J]. Science, 1984,224(4656) : 1403-1406. 被引量:1
  • 6Kim R,Emi M, Matsuura K,et a. Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma[J]. Gan To Kagaku Ryoho, 2005,32 ( 11 ) : 1540-1545. 被引量:1
  • 7Martmez-Arribas F,Alvarez T,Del Val G,et al. Bcl-2 expre- ssion in breast cancer: a comparative study at the mRNA and protein level[J]. Anticancer Res, 2007,27 ( 1 A): 219-222. 被引量:1
  • 8dos Santos LG, Lopes-Costa PV,dos Santos AR, et al. Bcl-2 oncogene expression in estrogen receptor-positive andnegative breast cancinoma[J]. Eur J Gynaecol On- col,2008,29(5) :459-461. 被引量:1
  • 9Kleinberg DL,Ameri P,Singh B.Pasireotide,an IGF-I action inhibitor,prevents growth hormone and estradiol-induced mammary hyperplasia[J].Pituitary,2011,14(1):44. 被引量:1
  • 10haiyan Jiao, chunlian Liu3, Weidong guo, et al. Association of CYP1B1 polymorphisms with Breast cancer: A case--control study in the Han population in ningxia Hui Autonomous Region, p. R. china [J]. Biomarker Insights, 2010,5 : 21-27. 被引量:1

引证文献7

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部